ADARx Pharmaceuticals, Inc.

ADRXReported to SECin USCIK 0001802369Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 94. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 94
Form 4 lines at ADARx Pharmaceuticals, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Chimovits Erez—Conversionnothing paid256,448 sharesSep 30, 2026Chimovits Ereznothing paidConversion · Sep 30Conversion256,448Sep 30, 2026
Chimovits Erez—Conversionnothing paid513,067 sharesSep 30, 2026Chimovits Ereznothing paidConversion · Sep 30Conversion513,067Sep 30, 2026
Chimovits Erez—Conversionnothing paid1,333,975 sharesSep 30, 2026Chimovits Ereznothing paidConversion · Sep 30Conversion1,333,975Sep 30, 2026
Chimovits Erez—Conversionnothing paid7,127,019 sharesSep 30, 2026Chimovits Ereznothing paidConversion · Sep 30Conversion7,127,019Sep 30, 2026
Chimovits Erez—Open-market buy$1,045,77261,516 sharesSep 30, 2026Chimovits Erez$1,045,772Buy · Sep 30Open-market buy61,516Sep 30, 2026